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Abstract
Epithelial-mesenchymal transition (EMT) plays a key role in cancer metastasis. This
process is a complex, multi-functional, and tightly regulated developmental program.
EMT has been extensively investigated, but the molecular regulation of its signaling
pathway is highly complex. In this study, the different elements of EMT cascades that
could be targeted were determined. Difficulties in translating the preclinical findings in
routine clinic were also distinguished. Future research will provide insights into the
activation and regulation of various EMT programs in different tumor types and at
distinct stages of tumor development. These results will likely facilitate the develop‐
ment of early detection strategies and improve the therapeutic targeting of malignant
solid tumors.
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1. Introduction
Cancer metastasis is the major cause of cancer morbidity and mortality. This process ac‐
counts for approximately 90% of cancer deaths. Epithelial-mesenchymal transition (EMT) is a
characteristic of the majority of metastatic cells. EMT is a natural transdifferentiation mecha‐
nism that governs changes in cell states along the epithelial versus mesenchymal axes and
confers epithelial-mesenchymal plasticity upon epithelial cells. In particular, epithelial cells
are transformed from highly differentiated, polarized, and organized cells into undifferenti‐
ated, isolated, and mesenchymal-like cells with migratory and invasive properties. In this
chapter, we summarize evidence supporting the widespread involvement of EMT in tumor
pathogenesis and the regulation of cancer metastasis.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. EMT: a naturally occurring transdifferentiation program
Normal adult tissues in terminally differentiated cells have been reprogrammed into pluripo‐
tent stem cells in the past 10 years [1, 2]. This process has resulted in the wide acceptance of
the initial hypothesis that nearly any type of dedifferentiation or transdifferentiation is possible
if the ectopic expression of a transcription factor is properly combined into adult cells. The
successful experiments on reprogramming have led to the exploration of the factors that
change the state of cells in nature rather than forced to ectopic gene expression.
EMT is the most important cell biology program among naturally occurring transdifferentia‐
tion programs. This process converts epithelial cells into mesenchymal derivatives, which is
the reverse process of mesenchymal-epithelial transformation (MET) [3]. Accumulated
evidence for the past two decades has suggested that EMT occurs during development to
ensure the interconversions of cells utilized in the formation of different types of cells, thereby
forming the organs of organization and complex multicellular organisms [3, 4]. This cell
biological program is orchestrated by a group of transcription factors (EMT-TFs), such as the
Snail, Twist, and Zeb families [4, 5].
Two other aspects of EMT are worthy to be discussed in detail. The EMT program in some
epithelial tissues is apparently correlated with the residence of cells in stem cell-like states.
Moreover, versions of the EMT program are adopted by cancer cells to obtain a series of
processes associated with higher levels of malignancy. EMT exhibits the presence of mechan‐
ical connections between an individual and the pathogenesis of cancer. These processes prior
to EMT are insignificant.
EMT governs changes in cell states along the epithelial versus mesenchymal axes and converts
epithelial cells to mesenchymal cells when this program is fully executed. Weinberg described
the extreme poles of the epithelial versus mesenchymal axes. Epithelial cells, frequently with
polygonal shapes in monolayer culture, are polarized along their apical-basal axis and are
tightly connected with one another laterally via adherens and tight junctions in vivo. These
lateral ties can ensure the structural integrity of epithelial cell sheets. By contrast, full mesen‐
chymal cells exhibit spindle-like morphology with no sign of apical-basal polarity. These cells
are loosely attached to the surrounding extracellular matrix (ECM) through focal adhesions.
These features can help improve motility and explain the invasion of mesenchymal cells
relative to their epithelial counterparts.
The deep layer of biological contact between epithelial and mesenchymal cells is determined
by the differences in their respective transcription programs. These programs also control the
expression of other gene products and key structural proteins, including those involved in the
maintenance of the cytoskeleton and the strengthening of cell-cell adhesion [3–5]. Thus,
epithelial cells express different types of keratin to form intermediate filaments, whereas
vimentin constitutes the intermediate filament protein of mesenchymal cells. The expression
of cell adhesion molecules and polarized complexes in mesenchymal cells is generally
inhibited. EMT is marked by the replacement of E-cadherin by N-cadherin, which leads to the
formation of weak cell adhesion between adjacent cells.
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EMT can be significantly and rapidly activated in epithelial cells in response to physiological
signals in a cell autonomous or non-cell autonomous manner. When gastrulation is used as an
example, EMT responds to the induction signal as follows. The program is activated in
ectodermal epithelial cells and completely converts epithelial cells into mesoderm mesenchy‐
mal cells, such as fibroblast growth factor and Wnt signaling pathway [6]. Similarly, EMT can
be rapidly activated in adult tissues; it reacts to wounding and promotes rapid wound healing.
This process is necessary to reconstruct the epithelial barrier that is essential for protecting
internal organs from external injury [7]. Such rapid conversion between epithelial and
mesenchymal states suggests the plasticity of epithelial cells, which facilitates their response
to EMT-inducing signals. In addition, this plasticity demonstrates that residence in one of these
two states is maintained in a metastable manner, with complex molecular and cellular
mechanisms to ensure that a cell is in one or another state for a long period.
The description of EMT as a binary that shifts cells from a fully epithelial state into a fully
mesenchymal state misreads the normal actions of this program. EMT is typically only from
a fully epithelial state to a partially mesenchymal state, with certain key epithelial markers
retained [8, 9]. Nevertheless, obtaining even a subset of mesenchymal traits to endow cells that
previously resided in a fully epithelial state with a suite of mesenchymal traits will produce
far-reaching effect on their biology.
3. EMT and cancer pathogenesis
Nearly 80% of malignant tumors are derived from epithelial tissues, which produce common
cancers, such as tumors of the lung, colon, breast, pancreas, prostate, bladder, ovary, kidney,
and liver. The epithelial states of the corresponding normal cells of origin in each determined
case sustain the expression of cytokeratin and E-cadherin, which are signs of the epithelial
states of early tumor tissues. In addition, tumor cells in early tumors remain the key biological
phenotypes of epithelial cells, such as a lack of motility and capability to form a continuous
cell sheet. These qualities exhibit a sharp contrast with those of advanced cancer cells, which
are products of a complex succession process that is frequently referred to as “tumor progres‐
sion.” Highly invasive tumor cells present mesenchymal features, such as motility and
invasion, and the latter is associated with metastasis [10–12]. The acquisition of these malignant
features at the mechanism level can be explained by activating EMT, which is previously
dormant in tumor cells during tumor progression.
The acquisition of mesenchymal features in breast cancer is positively correlated with tumor
progression and an aggressive subtype of the disease [13, 14]. Investigating a large body of
loss-of-function and gain-of-function in xenograft tumor models is a direct means to describe
the link between the activation of EMT and the degree of malignancy of a tumor. The con‐
sumption of EMT-TFS, such as Twist, Snail, and Zinc finger E-box binding homeobox 1 (ZEB1),
in both human and mouse breast cancer cell lines significantly inhibits the metastatic dissem‐
ination, whether the site is the primary site of tumor formation (e.g., mammary fat pad mass)
or after experimental introduction of cancer cells into venous circulation (i.e., tail-vein
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injection). By contrast, the ectopic activation of EMT can enhance metastatic dissemination of
orthotopically implanted human breast cancer cells by forcing the expression of EMT-TFS [15–
17].
EMT in patients with breast cancer does not only promote systemic dissemination but also
function as a major factor of drug resistance and disease recurrence [18, 19]. A similar phe‐
nomenon has been observed in a mouse model of Her2-induced tumors in which Snail EMT-
TF can be autoactivated in recurrent malignancy in vivo and make the tumors highly
mesenchymal phenotype [20]. The results evidently show an association between EMT
activation and tumor relapse. Moreover, the link between EMT activation and enhanced
tumorigenicity has been verified in various human cancer cell lines [21]. The inhibition of
epithelial-mesenchymal plasticity suppresses the valid transition of carcinoma cells from a
weakly tumorigenic into a highly tumorigenic state by blocking the activation of Zeb1 EMT-
TF; that is, a state where tumor-initiating cells demonstrate their improved capabilities [22].
Recent studies have associated EMT with the acquisition of immunosuppressive capabilities
in various types of cancers. The expression of Snail EMT-TF in melanoma can simultaneously
inhibit the differentiation of cytotoxic T cells and induce the immune inhibition of the forma‐
tion of regulatory T cells; the latter effect is mediated through the production of platelets [23].
Meanwhile, EMT in breast cancer cells enhances the resistance of tumor cells to cytotoxic T
cell-mediated lysis, which at least partially induces autophagy [24, 25]. The activation of EMT-
TF ZEB1 in lung cancer cells has been linked to the upregulation of programmed death ligand
1 (PD-L1), which is an immunosuppressive molecule that can block tumor-infiltrating
lymphocyte attack [26].
EMT activation has a pleiotropic function in driving cancer progression, and an increasing
number of reports confirm that invasive cancer is related to various types of aggressive
carcinoma cells. Thus, we believe that all carcinomas essentially develop traits that are related
with malignancy through the activation of an EMT program in their constituent neoplastic
cells. However, the EMT program associated with common cancers has not yet been deter‐
mined because many clinical pathologists doubt the existence of this program and its role in
the production of high-grade cancer [27]. Such reluctance primarily originates from the fact
that all markers of clinical biopsy are difficult to score. Although scoring will be possible, cancer
cells that underwent EMT are also difficult to distinguish from normal host tissues and adjacent
tumor stromal cells. Many fibroblasts and myofibroblasts self-express EMT-related markers.
Clear evidence of this program during tumor development can be obtained from cell detection
that co-express both mesenchymal and epithelial traits with certain retained epithelial markers
inherited from their fully epithelial precursors because cancer cells frequently experience the
only part of the EMT program. Recent analysis suggests that all subtypes of invasive breast
cancer tumor cells exhibit both epithelial and mesenchymal characteristics as shown by the in
situ hybridization in human breast cancer specimens of pooled epithelial and mesenchymal
markers [28]. In addition, a part of the circulating tumor cells is isolated from the peripheral
blood of patients with advanced prostate and breast cancers, and they also co-express both
epithelial and mesenchymal markers [28–30].
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4. EMT and tumor metastasis
Through the blood or lymphatic system, tumor cells can migrate far from the primary site and
then settle and grow in a remote site to complete tumor metastasis. This process plays a key
role in tumor disease, malignance level, and death of over 90% of tumor patients. Several
questionnaires have shown the low efficiency of tumor metastasis. The majority of tumor cells
can fall off into the blood or lymphatic system, such that only a small portion can form micro
metastases, and even fewer can achieve actual metastases and present specific organ affinity.
Moreover, the metastatic times of different tumors are not the same [31]. Thus, understanding
this process is significant, and the importance of EMT should be discussed from different
aspects.
EMT is a characteristic of most metastatic cells [32]. In particular, highly differentiated
epithelial cells are converted into undifferentiated and isolated ectomesenchymal cells with
migration and invasive properties. Migration is one of the four basic steps in tumor cell
metastasis. Various substances, such as secretion factors, growth factors, and ECM compo‐
nents, can stimulate the migration of tumor cells. Cell migration stimulated by these substances
can be divided into random and directed migrations. Thus, tumor cells can migrate and
metastasize. The migration capability of tumor cells is related to their potential to metastasize.
The density of the negative charges that separate from the surface of the tumor cells increases,
which enhances electrostatic repulsion between cells. This process facilitates the removal of
tumor cells into a free state from the tumor tissue. The adhesion of molecules on the surface
of tumor cells is mediated by cell adhesion molecules, namely selectins, integrins, Ig super‐
family, and cadherin [33]. Intercellular adhesion capability decreases in the same type, which
leads to the detachment of tumor cells from the primary tumor and the abnormal intercellular
adhesion contact with the implantation of tumor cells in the vascular wall. Invasion is the
important biological characteristic of malignant tumors. Every organization or organ has its
own structure. Tumor cells that invade an organ should respond to environmental stress, such
as the lack of oxygen and nutrients, low pH, active oxygen free radicals, and inflammation
regulatory factor. When the invasive capability is strong, the degree of tumor malignancy will
be high. Epithelial cells lose the characteristics of the epithelial cells of ectomesenchymal cells,
and the phenotype EMT process is the molecular basis of cancer stem cell invasion and
metastasis. In addition, during tumor development, many tumor cells exhibit changes in good
plasticity through morphology and phenotype transformation, such as collective amoeboid
transition (CAT) and mesenchymal-to-amoeboid transition (MAT) [34]. EMT is a transient
dynamic process that is influenced by the microenvironment. Furthermore, in vitro studies are
necessary to build an improved genetic mouse model and reliable marker for EMT to realize
real-time monitoring of the body, understand the mechanism of tumor evolution and EMT,
establish new EMT signs, and to explore the role of transcription factors in the induction of
EMT [35]. The loss of epithelial cell polarity during EMT reduces contact between the envi‐
ronment and stromal cells. This process enhances cell migration and mobility, which results
in mesenchymal phenotypes. Moreover, changes in cell phenotype, coupled with an alteration
in the expression levels of E-cadherin, vimentin, N-cadherin, and α-SMA, among others, in
particular, a drop in E-cadherin level, can reduce the adhesion of cells, which facilitates the
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invasion and metastasis of cells. The loss of E-cadherin expression has been considered the
most notable feature of EMT [36]. EMT presents increased opportunities for cell metastasis
during tumorigenesis, probably because of its loose cell characteristics. EMT can promote the
transfer of various tumor cells. Tumor metastasis includes several steps, such as attacks that
are the precondition for cell transfer. EMT plays an important role during tumor invasion.
Non-invasive tumors are turned into highly invasive tumors when the E-cadherin protein of
tumor cells is cut. Experiments have established EMT marks in some tumor cells in metastases.
Snail, Twist, and ZEBl transcription factors closely linked with EMT can enhance invasion and
promote the degradation of E-cadherin. EMT is the interaction between tumor cells and
adjacent tumor-associated stromal cells caused by the induction of the transcription factor in
the tumor cells. The activation of tumor EMT typically occurs during signal swaps between
tumor cells and adjacent stromal cells. The progression of primary tumor cells can raise each
model into the surrounding stroma. The recruitment of cells form a “reactive” matrix, induce
the release of EMT signals, and start tumor cells by activating the EMT transcription factors
[37]. Figure 1 shows the tumor metastasis and EMT.
Figure 1. In EMT processes, tumor cells change from epithelial-like cells to mesenchymal-like cells and get the ability
to metastasis.
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5. EMT-activating transcription factors in cancer
Many transcription factors can induce EMT. Molecular reprogramming during an EMT is
caused by three groups of transcription factors, namely the Snail, Twist, and ZEB families [38].
The Snail family includes Snail1, Snail2 (Slug), and Snail3 (Smuc). These factors regulate
epithelial and mesenchymal markers [39, 40]. Snail1 induces signal to initiate EMT [41, 42].
These factors inhibit other epithelial markers that affect E-cadherin and bind to the E-cadherin
promoter to inhibit its transcription. The Snail factors activate the expression of mesenchymal-
like and pro-invasive genes that promote cell migration [43].
Snail factors are absent in normal epithelial cells. Snail1 is expressed higher than Snail2 and
Snail3. An upregulated nuclear Snail1 expression is associated with tumor progression and
can be found in the cytoplasm of several carcinomas. Snail1 staining is found among fibroblast-
like cells, endothelial cells at the peritumoral stroma, and inflammation of colorectal carcino‐
mas [44]. Snail1 promotes the recurrence of Her2/neu-induced breast tumors in mice, and its
mesenchymal-like characteristics are exhibited in recurrent human carcinomas [45]. Therefore,
recurrent breast carcinomas are induced by Snail1 spontaneously. High level of Snail1 is an
independent predictor for reduced relapse-free survival in breast cancer patients. This factor
is considered an independent prognostic factor for worst evolution and poor survival in many
carcinomas [43].
Twist factor induces EMT by influencing other EMT-ATFs. Twist1 represses E-cadherin by
inducing Snail1 or Snail2 and then binding to its promoter [46–48]. The knockdown of Twist1
in breast cancer cells represses the metastasis in xenograft models, but does not influence the
formation of primary tumors [49]. Twist1 induces N-cadherin by driving its transcription and
the mechanisms of post-transcription [50, 51]. Twist1 promotes the expression of mesenchymal
markers without eliciting an N-cadherin/E-cadherin switch in glioblastoma cells [52]. In cell
motility, the excessive expression of Twist1 upregulates the expression of cytoskeletal and
ECM genes.
Twist1 and Twist2 are upregulated at the invasive front of carcinomas in cancer and stromal
cells [53–55]. These factors are absent in normal epithelium but are induced in many human
carcinomas, such as those of the digestive tract, liver, breast, ovary endometrium, and prostate
[43]. Twist factors are upregulated in the cytoplasm and nuclei of cancer cells. Twist factors
are independent prognostic factors for increased tumor recurrence, tumor aggressiveness, and
the low survival rate of patients [49, 53, 56]. Twist and Snail factors play distinct but collabo‐
rative roles among EMT-ATFs.
The ZEB family includes zinc finger/homeodomain proteins, namely ZEB1 and ZEB2. The
expression of ZEB factors drives an EMT by activating mesenchymal properties and repressing
epithelial markers [43].
ZEB1 and ZEB2 bind to E-box sequences in the E-cadherin promoter but recruit different sets
of co-repressors, namely SWI/SNF and CtBP for ZEB1 and NuRD and CtBP for ZEB2. ZEB
proteins bind and repress the promoters of epithelial markers, such as R- and P-cadherins, gap
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junctions (connexins 26 and 31), cell polarity markers (Crumbs3, Pals1-associated tight junction
protein, and lethal giant larvae homologue 2), desmosomes (plakophilin 3, desmoplakin), and
components of tight junctions (claudin 7, occludin, junctional adhesion molecule 1, and zonula
occludens protein 3). ZEB proteins activate mesenchymal markers, such as N-cadherin and
vimentin [43]. ZEB1 and ZEB2 repress epithelial splicing regulatory proteins-1 and 2, the
overexpression of which inhibits EMT [57].
ZEB1 inhibits epithelial phenotype, although this factor is found in isolated fibroblasts and
immune cells in the interstitial matrix. This factor is not expressed in normal epithelium and
well-differentiated carcinomas that express E-cadherin [58, 59]. ZEB1 is highly expressed in
invading dedifferentiated cancer cells of many tumors, such as colorectal, breast, liver,
endometrial, lung, prostate, and pancreatic carcinomas. ZEB1 and ZEB2 are expressed by
stromal cells in epithelial tissues and organs of normal E-cadherin-positive epithelial cells [60].
ZEB-dependent paracrine signaling from the stroma can cooperate in E-cadherin repression
in other parts of the tumor [61].
Figure 2. The main signaling pathways involved in EMT.
Other transcription factors also induce EMT and tumor invasiveness. The homeobox factor
goosecoid induces EMT by activating mesenchymal genes and repressing epithelial markers
[62]. TGF-β induces goosecoid in breast epithelial cells, and goosecoid is overexpressed in
ductal breast carcinomas and atypical ductal hyperplasia [62]. Figure 2 shows the main
signaling pathways involved in EMT.
6. EMT in a clinical perspective
EMT significantly affects metastasis in cancers [63]. This process has attracted increasing
attention because metastasis is vital in cancer recurrence and in death caused by cancer [64,
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65]. In addition, understanding this process is important to determine medical diagnosis and
treatment approach. Notably, sufficient information on biomarkers can lead to accurate
forecast and precise therapeutic methods for metastases. Hence, proper diagnostic and
therapeutic treatment for patients with early-stage cancer can promote good prognosis and
prolong survival time to further improve the quality of life of patients [66, 67]. Furthermore,
TBLR1, Sam68, SNAI1, Twist 2, etc. have been diagnosed markers or prognostic factors. This
information is clinically important to predict survival and provide promising therapeutic
targets for patients with early stage cancer [68, 69].
Sulforaphane or salinomycin treatment changes the stemness properties of cancer stem cells
(CSCs), which may have been caused by the regulation of the expression of a special gene or
protein. Sulforaphane downregulates Twist-1 and vimentin. By contrast, salinomycin treat‐
ment does not only significantly reduce vimentin level but also induce and upregulate E-
cadherin expression in special cancer cell lines. Various reports have indicated a key role of E-
cadherin in EMT. Thus, studying these cadherins can be a promising strategy [70, 71].
Epithelial cancer cells tend to differentiate to acquire invasive and stem cell-like properties.
Thus, EMT regulators may function as therapeutic targets of cancer progression and recur‐
rence. EMT-TFs, such as Twist, Snail, and ZEB, will be regarded as potent therapeutic targets
for pharmacologic inhibition. Traditionally, EMT regulators are nearly impossible to target;
however, evidence suggests that molecular links can offer the possibility for targeting regu‐
lation as a therapeutic intervention of EMT among metabolic adaptation, epigenetic alteration,
and EMT [4, 72–74].
EMT significantly affects epigenome restructuring. Thus, epigenetic therapies can be used to
realize the pharmacologic inhibition of EMT, which makes EMT sensitive to chemotherapy.
In recent years, potential EMT inhibitors function as an effective chemotherapeutic sensitive
agent, such as HDAC enzymes LBH589 [75]. In addition, histone demethylase LSD1 epigenetic
modifiers offer important information on the survival of EMT by reducing invasiveness or
inhibiting the transfer function. Thus, inhibiting LSD1 [76] may lead to improved survival
because of the inhibition of invasiveness and metastasis [76].
Although epigenetic therapies exhibit considerable potential for clinical applications, the
clinical application of epigenetic drugs remains ambiguous because of its unclear mechanism.
The mechanism of epigenetic drugs should be investigated further. Therefore, the enhance‐
ment of specificity may solve the potential problem on the treatment of particular epigenetic
targets in the future [74].
Drugs are likely to become anti-cancer drugs in clinical applications. Further study on the
clinical trials of cancer has shown that metformin arouses attention as a promising anti-cancer
agent [77, 78]. Metformin involves systemic effects, such as reducing insulin levels and acting
on one-carbon metabolism. This metabolism will be explored with epigenetic alterations based
on the connection between metabolism and the epigenetic state of cells [79].
Decitabine, which is a DNA methyltransferase (DNMT) inhibitor, suppresses the migration
capacities of SDH-mutant cells. This inhibition is evidently displayed by succinate abnormal
accumulation in epigenetic dysregulation and the resultant EMT. Mutant enzymes to directly
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explore the inhibition approach for SDH- and FH-associated cancers are worthy to be explored
[80].
7. Epigenetic modification and EMT
EMT is a comprehensive reprogramming during tumor development. This process involves
metabolism, epigenetics, and differentiation. In a specific tumor microenvironment, EMT-
dedifferentiated cells escape the primary tumor after they acquire migration and invasion
capabilities, invade the surrounding tissues, enter into the blood or lymphatic vessels, and
settle in distant organs. EMT converts differentiated epithelial cancer cells to an undifferenti‐
ated state, thereby expressing stem cell markers and acquiring stem cell-like functions. This
process is reversible, and mesenchymal cells can differentiate into epithelial phenotypes. Thus,
an important process is developed in the macroscopic metastases in different organs.
DNA methylation, histone modification, and microRNA are the three types of epigenetic
modification. Many studies have shown that epigenetic modifications play a key role in tumor
metastasis [81]. The downregulation of E-cadherin (a cell adhesion molecule) expression
during EMT is an important feature. Therefore, the precise regulation of E-cadherin expression
via epigenetic modifications is extremely important to the occurrence of EMT. Several EMT-
related transcription factors are recruited as E-cadherin gene promoter, which inhibits
transcription [4]. Studies have shown that E-cadherin can be inhibited by the synergy of
various histone modification enzymes. The E-cadherin gene promoter is inhibited to different
extents to silence E-cadherin expression [82].
The characteristics of EMT are reversible in the type of stem cells and malignant features.
Tumor stem cells are unique undifferentiated cells, rather than increasing diffusion, compared
with most differentiated epithelial cells. The diffusion of anabolic needs is related to the
maintenance of an undifferentiated state, which may be metabolic alterations of the links
between EMT and tumor [83]. A change in cell metabolism is an important sign of cancer. The
best metabolic phenotype in tumor cell is characterized by the Warburg effect, which proves
that ATP is not the only metabolite of tumor cells [84]. Further studies have shown that aerobic
glycolysis can better satisfy the basic needs of cell division, known as the post-Warburg model.
This process is not only associated with cancer and normal cell proliferation, but also inhibits
mitotic cell differentiation. In the same inducers, bunah and inactivated tumor suppressor
genes, even oxygen glycolysis capability increased in the EMT, can be attributed to cell
undifferentiated state. The appropriate energy level is sufficient for biosynthesis precursor,
balancing normal state, and maintaining an undifferentiated state.
Epigenetic modifications are complex, dynamic, and connected with the extracellular envi‐
ronment and nuclear transcription. Energy availability is extremely important. Energy-rich
substances, such as carbohydrates and fats, in the human body translate into ATP, along with
a large number of metabolites, such as glycolysis and fatty acid oxidation. These metabolites
can also drive epigenetic modifications in gene expression. A change in the intermediate
metabolites of EMT may not be simple. Metabolic reprogramming plays a role in the energy
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crisis causation of cancer cells. This process determines the epigenetic sand by modifying the
undifferentiated state of the chromatin structure. Reprogrammed genes and the change in gene
expression influence EMT markers and metabolic enzymes to overcome the local restriction
to obtain energy in the distant tissues and organs. The microenvironment is significant for the
EMT metastasis potential of cancer cells in reprogramming metabolism, epigenetics, and
differentiation. Hepatic, epidermal, and fibroblast growth factors activate and maintain the
EMT process. The cancer microenvironment growth factor activity generally regulates the
interaction between metabolism and EMT to coordinate cell differentiation and metabolism.
The transfer process is the key to the reversibility of EMT based on our previous study, in
which EMT regulation is mainly at the transcription level [4]. However, numerous molecular
mechanisms cooperate to change the behavior of tumor cells. In particular, the role of the
transcription regulation of EMT in the regulation and control of gene expression of the
transcription of alternative splicing is extremely important. Spliceosome assembly has
experienced gradual, composition, and structure changes required for normal maintenance.
The correlation of alternative splicing tumor progression becomes apparent. In fact, all major
cell biology deregulations of cancer are related to the changes in the alternative splicing of a
specific gene profile. Modifying the splicing expression and activities supervised by SR and
hnRNP provides the main source of changes in the stitching program observed in cancer cells
[85].
Malignant EMT plays a key role during transfer, and the alternative splicing program affects
the cell phenotype, including protein, cell adhesion, and cytoskeleton dynamics, influences
tumor microenvironment, and controls tumor metastasis formation. Cancer gene mutations
initiate processes, and epigenetic changes will be necessary to promote cancer. The change in
the epigenome improves the transfer of cells.
In general, cells, which are affected by external environment signals, satisfy the internal
requirements of nutrient and energy metabolism, as well as cooperate actively to promote the
occurrence of EMT. Thus, tumor metabolic adaptations and EMT are different mechanisms for
the same target cells to survive and grow. A close link and high correlation exist between
metabolic reprogramming EMT and the similarity rule and fly mechanism.
8. Regulatory role of microRNAs in EMT
MicroRNAs (miRNAs) are expressed endogenously as small, non-coding RNAs that regulate
various biological processes by modulating gene expression at the post-transcriptional level
[86]. MiRNAs play an important role in controlling tumor growth and progression. Some
miRNAs function as oncogenes and tumor suppressors. Moreover, miRNAs are also master
regulators of EMT and dynamically regulate balance between EMT and MET.
The miR-200 family consists of five miRNA sequences, namely miR-200a, miR-200b, miR-200c,
miR-141, and miR-429. Aggregated miRNAs that are expressed as two independent polycis‐
tronic pri-miRNA transcripts are as follows: miR-200a, miR-200b, and miR-429 (chromosome
1); and miR-200c and miR-141 (chromosome 12) [87].
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The autocrine TGF-β/ZEB/miR-200 signaling regulatory networks that control epithelial and
mesenchymal states change in the cells. ZEB1/2 and TGF-β exhibit strong correlation, and
negative correlations are detected between TGF-β and miR-200, as well as between ZEB1/2
and miR-200, in invasive ductal carcinomas [88]. ZEB1/2 can induce EMT by inhibiting various
epithelial genes [89].
Other miRNAs can directly target EMT transcription factors. MiR-205 in mammary cells
maintains epithelial differentiation [90–92]. MiR-29b in prostate cancer inhibits metastasis by
regulating the EMT signal. MiR-148a in hepatocellular carcinoma (HCC) cells can negatively
regulate Met/Snail signaling and prevent EMT and metastasis [93]. Snail and miR-34 form
another double feedback loop. EMT is induced by TGF-β, and an increase in Snail expression
can be inhibited by miR-34. A novel miR-203/SNAI1 feedback loop has also been reported in
breast cancer. These double feedback loops can enhance the balance between EMT activation
and control of the two states of the cell (epithelial and mesenchymal). A novel EMT network
that integrates the negative feedback loops, miR-203/Snai1, and miR-200/ZEB has been
proposed recently as a control epithelial cell plasticity switches during differentiation and
cancer [94]. The expression of miR-10b in metastatic breast cancer cells is shown to be induced
by the transcription factor Twist, which binds directly to the putative promoter of miR-10b.
Twist-induced miR-10b inhibits the translation of mRNA encoding homeobox D10, which
results in an increased expression of RHOC, which is a well-characterized prometastatic gene
[95].
Many miRNAs interfere with EMT by targeting the structures of cell components [96–98].
MiR-155 is the direct transcriptional target of TGF-β/Smad 4 signaling [99]. MiR-155 ectopic
expression can reduce the RhoA (Ras homolog gene families, member A) protein, a small
GTPase protein, to modulate the formation of tight junctions in the formation of stress fibers
of the actin cytoskeleton during expression and destruction [100]. The activation of miR-31 in
establishing metastases results in the regression of metastasis and the enhancement of the
survival of patients. In addition, the induction of miR-31 can reduce the metastatic potential
of cancer cells by targeting the RhoA [101]. The upregulation of miR-9 and direct repression
of E-cadherin-1 (CDH1) in human breast cancer cells are involved in the regulation of cell-cell
adhesion, migration, and the epithelial cell proliferation mechanism of calcium-dependent
protein. CDH1 repression results in increased cell motility and invasion [102].
9. Inhibitors of EMT
Numerous tumor EMT inhibitors have been found in this study, and many of which are
difficult to apply clinically because of stability and targeting isssues. TGF-β is an important
factor in regulating EMT.
Various EMT inhibitors have been found in the TGF-β signaling pathway. Thyroid transcrip‐
tion factor-1 is a protein encoded by the NKX2-1 gene in normal tissues that can inhibit the
secretion of TGF-β, which increases the expression of E-cadherin in lung cancer cells.
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MMPs are other key factors in the induction of EMT. The inhibitors of MMPs play an important
role in blocking EMT development in tumor cells. Several MMP inhibitors, which have been
tested in clinical trials, can prevent EMT in cell experiments in vitro and inhibit tumor
progression in in vivo animal experiments. Orlistat Plymouth, one of the MMP inhibitors, has
a relatively significant effect on non-small cell lung cancer, colorectal cancer, and glioma, both
in in vitro cell experiments and in vivo animal experiments. Conducting combination chemo‐
therapy with marimastat, captopril, and Fragmin exerts a certain effect on the treatment of
advanced kidney cancer. The human body itself can also synthesize a special kind of MMP
inhibitor, a tissue inhibitor of metalloproteinase (tissue inhibitors of metalloproteinases,
TIMPs). TIMPs, which are produced using genetic engineering technology, can also be used
as targeted drugs to treat tumors caused by the imbalance among MMPs and inhibit the
progression of EMT in tumor cells.
Certain phytochemicals or food substances exhibit anti-cancer [103, 104] and anti-EMT
properties [105]. For example, AIMs (anthocyanidins) and Morusin (a prenylated flavonoid),
which are isolated from the fruits of Vitis coignetiae Pulliat (known as meoru in Korea) and the
root bark of Morus australis (Moraceae), respectively, demonstrate anti-cancer activities by
inhibiting EMT through the suppression of nuclear factor (NF)-κB activity [106–108].
AIMs can inhibit NF-κB in a dose-dependent manner, and MMP-9 (EMT marker) can be
regulated by NF-κB preferentially [109]. IκBα phosphorylation and GSK-3 activity can also be
suppressed by increasing the levels of AIMs [110]. Moreover, AIM downregulates mesenchy‐
mal markers, such as Vim1, N-cadherin, and SNAI, as well as upregulates epithelial markers,
such as E-cadherin [110]. The morphological changes induced by TNF-α [110] are also inhibited
by AIM. The suppression of the migratory and invasive properties of cervical cells by AIM has
also been reported. Cervical cancer contains a heterogeneous population of cells called CSCs.
CSCs are cells with chemotherapy- and radiotherapy-resistant properties and are involved in
tumor recurrence, metastasis, and high mortality [111, 112]. Morusin, however, are reported
to be cytotoxic to several cancer cell lines, including cervical cells. Morusin can inhibit
migration and proliferation by inhibiting tumor sphere formation through the inhibition of
the NF-kB pathway.
Recent studies in our laboratory have found several EMT inhibitors, including tetracycline and
some natural products. The gelatinase inhibitor doxycycline is the prototypical anti-tumor
antibiotic. We have investigated the effects of doxycycline on the migration, invasion, and
metastasis of human lung cancer cell lines and in a mouse model. We have also measured the
effect of doxycycline on the transcription of EMT markers and used immunohistochemistry to
determine whether EMT reversal is associated with doxycycline inhibition. Doxycycline dose-
dependently inhibits the proliferation, migration, and invasion of NCI-H446 human small cell
lung cancer cells. It also suppresses tumor growth from NCI-H446 and A549 lung cancer cell
xenografts without altering body weight, inhibits Lewis lung carcinoma cell migration, and
prolongs survival. The activities of the transcription factors Twist1/2, SNAI1/2, AP1, NF-κB,
and Stat3 are suppressed by doxycycline, which reverses EMT and inhibits signal transduction,
thereby suppressing tumor growth and metastasis. Our data demonstrate functional targeting
of transcription factors by doxycycline to reverse EMT and suppress tumor proliferation and
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metastasis. Thus, doxycycline selectively targets malignant tumors and reduces their meta‐
static potential with less cytotoxicity in lung cancer patients.
Apigenin is a naturally occurring compound with anti-inflammatory, antioxidant, and
anticancer properties. We have investigated the effects of apigenin on migration and metastasis
in experimental HCC cell lines in vitro and in vivo. Apigenin dose-dependently inhibits the
proliferation, migration, and invasion of PLC and Bel-7402 human HCC cells. It also suppresses
tumor growth in PLC cell xenografts without altering body weight, thereby prolonging
survival. Apigenin reduces Snai1 and NF-κB expression, reversed increases in EMT marker
levels, increases cellular adhesion, regulates actin polymerization and cell migration, and
inhibits invasion and migration of HCC cells. Therefore, apigenin may inhibit EMT by
inhibiting the NF-κB/Snail pathway in human HCC. Table 1 shows some EMT inhibitors found
in the last 3 years.
Molecules Tumor types Pathway References
Cyclin G2 Ovarian cancer Wnt/β-catenin Bernaudo et al. [113]
FOXO3a Prostate cancer Wnt/β-catenin Liu et al. [114]
sFRP4 Head and neck squamous cell
carcinoma
Wnt/β-catenin Warrier et al. [115]
sophocarpine Hepatocellular carcinoma AKT/GSK-3β/β-
catenin
Zhang et al. [116]
Bisdemethoxycurcumin Lung cancer TGF-β Xu et al. [117]
Ski Lung cancer TGF-β Yang et al. [118]
GRP78 Colon cancer TGF-β Zhang et al. [119]
Thymoquinone Breast cancer TGF-β Rajput et al. [120]
BMP-7 Cholangiocarcinoma TGF-β Duangkumpha et al. [121]
NDRG2 Colon cancer TGF-β Shen et al. [122]
Myrtucommulone-A and
thymoquinone
Bladder cancer and breast cancer PI3K Iskender et al. [123]
ING5 Breast cancer PI3K Zhao et al. [124]
α-Mangostin Pancreatic cancer PI3K Xu et al. [125]
NVP-BEZ235 Ovarian cancer PI3K Lin et al. [126]
IL-32θ Colon cancer STAT3 Bak et al. [127]
Luteolin Pancreatic cancer STAT3 Huang et al. [128]
FTY720 Cholangiocarcinoma STAT3 Lu et al. [129]
NDRG2 Breast cancer STAT3 Kim et al. [130]
Table 1. Some EMT inhibitors.
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